Idorsia Ltd (OTCMKTS:IDRSF) Short Interest Down 27.4% in September

Idorsia Ltd (OTCMKTS:IDRSF) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 975,400 shares, a decline of 27.4% from the August 31st total of 1,342,900 shares. Based on an average trading volume of 1,100 shares, the short-interest ratio is presently 886.7 days. Based on an average trading volume of 1,100 shares, the short-interest ratio is presently 886.7 days.

Analyst Ratings Changes

IDRSF has been the topic of several research reports. HC Wainwright raised Idorsia from a “neutral” rating to a “buy” rating in a research report on Monday, September 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Idorsia Stock Performance

Shares of IDRSF opened at $5.50 on Tuesday. The business has a 50-day simple moving average of $3.72 and a two-hundred day simple moving average of $2.47. Idorsia has a 52 week low of $0.70 and a 52 week high of $5.50.

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.